Genfit S.A.
genfit.frWhat Do They Do?
Develops drug candidates and diagnostic technologies for patients with severe liver diseases, including acute-on-chronic liver failure and rare, life-threatening conditions.
20-F for FY2024, filed Apr 29, 2025GENFIT is a biopharmaceutical group conducting preclinical and clinical research and development of drug candidates and diagnostic…View ↗
With its rich scientific heritage spanning more than two decades, the Group is a pioneer in the discovery and development of drugs for…View ↗
GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with severe liver diseases who have a…View ↗
Who Are Their Customers?
Drug and diagnostic rights go to partners: Ipsen licenses elafibranor, Terns holds rights in Greater China, and Labcorp licenses NIS4 technology for a laboratory test in the United States and Canada.
20-F for FY2024, filed Apr 29, 2025
Do Revenues Turn Into Profits?
Yes. It kept 2 cents of every revenue dollar as net income in .
20-F for FY2024, filed Apr 30, 2025
20-F for FY2024, filed Apr 30, 2025
EUR 1.5MView ↗
How Are They Changing?
Greater focus on acute liver disease
The earlier report grouped its work around cholestatic diseases, ACLF and diagnostics; the latest places greater emphasis on ACLF and other life-threatening liver diseases.
20-F for FY2021, filed Apr 29, 2022 20-F for FY2024, filed Apr 29, 2025Over the past several years, GENFIT has made a strategic pivot towards Acute-On-Chronic Liver Failure (ACLF) and other life-threatening…View ↗
Elafibranor commercialization
The earlier report described elafibranor as a PBC drug candidate licensed to Ipsen; the latest says Ipsen received marketing authorization and began commercialization.
20-F for FY2021, filed Apr 29, 2022 20-F for FY2024, filed Apr 29, 2025At the end of 2021, this franchise includes one Phase 3 program in PBC, with investigational drug candidate elafibranor, and one Phase 2…View ↗
Expanded diagnostic targets
The earlier diagnostics franchise focused exclusively on NASH; the latest also lists a diagnostic focused on blood ammonia levels.
20-F for FY2021, filed Apr 29, 2022 20-F for FY2024, filed Apr 29, 2025This franchise is currently exclusively focused on NASH and the main program aims at developing our non-invasive, blood-based diagnostic…View ↗
With its rich scientific heritage spanning more than two decades, the Group is a pioneer in the discovery and development of drugs for…View ↗
Loading...
